Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 676 press releases before 2019
-
MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
-
AstraZeneca and Bristol-Myers Squibb announce US FDA approval of FARXIGA™ (dapagliflozin)
-
AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR®
-
AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets
-
AstraZeneca statement in response to reports of a launch of esomeprazole strontium product in the US
-
AstraZeneca announces top-line results from phase III monotherapy study of lesinurad in gout patients
-
FDA Advisory Committee votes on investigational medicine metreleptin
-
FDA Advisory Committee recommends the investigational SGLT2 inhibitor dapagliflozin for treatment of type 2 diabetes in adults
-
AstraZeneca donates Brixham Environmental Laboratory to Plymouth University
-
European Commission approves Fluenz Tetra for the prevention of seasonal influenza in children
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
